Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

prevention

Novartis Gehry Building

NICE backs Cosentyx for ankylosing spondylitis

The immunotherapy is on course to be “one of the most successful launches in Novartis history”

- PMLiVE

Keytruda cleared in Europe for lung cancer

New second-line indication for Merck’s drug puts it in direct competition with BMS’ Opdivo

- PMLiVE

GSK and Google launch bioelectronics venture

Will develop electronic implants to treat chronic diseases, including diabetes

- PMLiVE

Dept of Health to launch sepsis awareness campaign across UK

Aims to transform public understanding and NHS handling of the condition

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

Bristol-Myers Squibb (BMS) building

NICE finalises record-breaking Opdivo/Yervoy appraisal

BMS’s immunotherapy combination receives recommendation in 24 days

Brextinction

Evolution predicts tragic consequences from the UK's choice

Wearables’ impact on cancer patients’ quality of life to be tested

Project sees the Memorial Sloan Kettering Cancer Center collaborate with Medidata

EU flag

EU proposes reforms to make first-in-human trials safer

New guideline revision paper “takes into account lessons learnt” from fatal Bial trial

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

- PMLiVE

Alzheimer’s: the numbers we cannot forget

In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Blue Latitude Health

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links